Effects of Warfarin Nomogram in initial phase warfarin patients at Charoenkrung Pracharak hospital
Article Sidebar
Main Article Content
Abstract
Most physicians initiate and adjust warfarin dose based on International Normalized Ratio (INR)and their clinical judgment. This study was conducted to investigate the effects of using warfarin nomograms in patients initiated warfarin at Charoenkrung Pracharak hospital. This study was a randomized controlled trial involving patients who started using warfarin while hospitalized at Charoenkrung Pracharak hospital from August to November 2023. The experimental group received the initiation and dosage adjustments of warfarin using the warfarin nomograms, while the control group had their warfarin initiation and dosage adjustments based on the physician's clinical judgment, analyzing the proportion of patients who achieved an INR between 2.0 and 3.0 within 14 days after warfarin initiation. From a total sample of 98 individuals, divided into control (49) and experimental (49) groups, Baseline characteristics of both groups were not significantly different except for gender. The research findings indicated a statistically significant difference between the experimental and control groups concerning the proportion of patients with INR values within the range of 2.0 to 3.0 within 14 days after receiving warfarin (44.9% and 24.5%, respectively, p=0.034). The use of warfarin nomograms for initiating and adjusting dosages allows patients to achieve their target INR range more effectively than starting and adjusting doses solely based on physician judgment. Additionally, the safety of using warfarin nomograms does not significantly differ from initiating and adjusting doses solely based on physician judgment.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Journal of TCI is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence, unless otherwise stated. Please read our Policies page for more information.
References
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692-711. https://doi.org/10.1161/01.CIR.0000063575.17904.4E
The Heart Association of Thailand under the Royal Patronage of H.M. Warfarin guideline. n.p.:2010.
Godoy LC, Tomlinson G, Abumuamar AM, Farkouh ME, Rudolph M, Billia F, et al. Association between time to therapeutic INR and length of stay following mechanical heart valve surgery. J Card Surg. 2022;37(1):62-9. https://doi.org/10.1111/jocs.16083
Anderson DR, Wilson SJ-A, Blundell J, Petrie D, Leighton R, Stanish W, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. J Bone Joint Surg Am. 2002;84(11):1992-7.
Asnis PD, Gardner MJ, Ranawat A, Leitzes AH, Peterson MG, Bass AR. The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. J Arthroplasty. 2007;22(2):213-8. https://doi.org/10.1016/j.arth.2006.03.006
Hotarawareekarn R. New dosage regimen for starting warfarin in patients with mechanical prostheticheart valve replacement at Rajavithi Hospital [Thesis]. Grad - E-Theses: Chulalongkorn University; 1997.
Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154(3):311-24. https://doi.org/10.1111/j.1365-2141.2011.08753.x
Dang M-TN, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39(6):1008-12. https://doi.org/10.1345/aph.1E566
Cohen J. CHAPTER 7 - Chi-Square tests for goodness of fit and contingency tables. In: Cohen J, editor. Statistical Power Analysis for the Behavioral Sciences: Academic Press; 1977. p. 215-71.
Kang H. Sample size determination and power analysis using the G*Power software. J Educ Eval Health Prof. 2021;18:17. https://doi.org/10.3352/jeehp.2021.18.17
Witt DM, Clark NP, Vazquez SR. Venous thromboembolism. In: DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V, editors. Pharmacotherapy: A Pathophysiologic Approach, 11e. New York, NY: McGraw-Hill Education; 2020.
Blann AD, Fitzmaurice DA, Lip GY. Anticoagulation in hospitals and general practice. BMJ. 2003;326(7381):153-6. https://doi.org/10.1136/bmj.326.7381.153
del Campo M, Roberts G. Changes in warfarin sensitivity during decompensated heart failure and chronic obstructive pulmonary disease. Ann Pharmacother. 2015;49(9):962-8. https://doi.org/10.1177/1060028015590438
Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J Hepatol. 2005;42(1, Supplement):S100-S7. https://doi.org/10.1016/j.jhep.2004.11.015
Efird LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, et al. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ: Cardiovasc Qual Outcomes. 2014;7(3):461-7. https://doi.org/10.1161/CIRCOUTCOMES.113.000817
Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109(6):481-8. https://doi.org/10.1016/S0002-9343(00)00545-3
Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Intern Emerg Med. 2012;7(3):193-9.
Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):8s-21s. https://doi.org/10.1378/chest.119.1_suppl.8S
Howard-Thompson A, Luckey A, George C, Choby BA, Self TH. Graves’ disease and treatment effects on warfarin anticoagulation. Case Rep Med. 2014;2014:1-6. https://doi.org/10.1155/2014/292468
Jantara S, Pattarawimonchai O, Juntaranimi P. Clinical factors associated with low, medium and high warfarin dose requirements in adult and older adult patients at Loei hospital. Srinagarind Med J. 2023;38(3):291-302. https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/258157
Kawai M, Harada M, Motoike Y, Koshikawa M, Ichikawa T, Watanabe E, et al. Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study. Int J Cardiol Heart Vasc. 2019;22:111-6.
Kellett HA, Sawers JSA, Boulton FE, Cholerton S, Park BK, Toft AD. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med. 1986;58(1):43-51.
Lee VW, You JH, Lee KK, Chau TS, Waye MM, Cheng G. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis. 2005;20(1):33-8. https://doi.org/10.1007/s11239-005-3121-8
Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56(5):823-31.
MerativeTM Micromedex® Drug Interaction Checking (warfarin).Merative, Ann Arbor, Michigan, USA.2023 Oct 15 [cited 2023 Oct 15]. Available from: https://www.micromedexsolutions.com/
Mueanjanjaem K. Optimum and clinical factors affecting the stable maintenance dose of warfarin at Ratchaburi Hospital. Hua Hin Med J. 2020;5(1):18-29. https://he01.tci-thaijo.org/index.php/hhsk/article/view/240517
Nakornchai W, Rojnuckarin P. Bleeding risk of warfarin therapy among cirrhotic patients. J Hematol Transfus Med. 2019;29:205-13.
Panompong K, Tonhongsa P. Factors predicting of warfarin dosage and Factors Related to International Normalized Ratio (INR) of the patients , Nong Phok hospital, Roi Et Province. J Res Health Innov Dev. 2021;2(3):109-20.
Rivey MP, Wood RD, Allington DR, Stratton TP, Erickson CC, Stenson TA. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health Syst Pharm. 1995;52(12):1310-6. https://doi.org/10.1093/ajhp/52.12.1310
Stephens MA, Self TH, Lancaster D, Nash T. Hypothyroidism: effect on warfarin anticoagulation. South Med J. 1989;82(12):1585-6.
Suwanawiboon B, Kongtim P, Chinthammitr Y, Ruchutrakool T, Wanachiwanawin W. The efficacy of 3-mg warfarin initiating dose in adult Thai patients, who required long-term anticoagulant therapy. J Med Assoc Thai. 2011;94 Suppl 1:S225-31.
Suwanawiboon B, Rotchanapanya W, Mahaprom K, Thongnoppakhun W, Lalerd Y, Limwongse C, et al. The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial. Hematology. 2022;27(1):95-104. https://doi.org/10.1080/16078454.2021.2019891
Tincani E, Mazzali F, Morini L. Hypoalbuminemia as a risk factor for over-anticoagulation. Am J Med. 2002;112(3):247-8. https://doi.org/10.1016/S0002-9343(01)00957-3
Tyson K, Hutchinson N, Williams S, Scutt G. Identification of clinical factors predicting warfarin sensitivity after cardiac surgery. Ther Adv Drug Saf. 2018;9(8):415-24. https://doi.org/10.1177/2042098618776541
Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis. 2013;36(1):96-101. https://doi.org/10.1007/s11239-012-0811-x
Wattanasombat S. Anticoagulant :Warfarin. TPHSJ. 2010;5:87-98.
Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009;114(5):952-6. https://doi.org/10.1111/j.1538-7836.2010.03756.x
Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010;8(4):744-9. https://doi.org/10.1111/j.1538-7836.2010.03756.x
Rovinelli RJ, Hambleton RK. On the use of content specialists in the assessment of criterion-referenced test item validity. Tijdschrift voor Onderwijsresearch. 1977;2(2):49-60.
Chamoun N, Macías CG, Donovan JL, Klugman R, Gore J, Salameh P, et al. Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge. J Thromb Thrombolysis. 2017;43(4):454-62. https://doi.org/10.1007/s11239-016-1462-0
Khoury G, Sheikh-Taha M. Effect of age and sex on warfarin dosing. Clin Pharmacol. 2014;6:103-6. https://doi.org/10.2147/CPAA.S66776
Freter S, Bowles SK. Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosage for prophylaxis after orthopaedic surgery on a geriatric rehabilitation unit. Can J Aging. 2005;24(4):443-7.
Yoo SH, Kwon SU, Jo MW, Kang DW, Kim JS. Age- and weight-adjusted warfarin initiation nomogram for ischaemic stroke patients. Eur J Neurol. 2012;19(12):1547-53. https://doi.org/10.1111/j.1468-1331.2012.03772.x